City Hall has given £22m to three life sciences and quantum projects. None is based in Lewisham; a south London health network is one of the partners.

City Hall has picked three projects to share £22 million of innovation money, two aimed at heart disease, diabetes and obesity and one at quantum technology, and none of them is based in Lewisham. The Mayor of London, Sadiq Khan, announced the awards on Monday 16 November, the first day of London Life Sciences Week. The closest link to the borough is the Health Innovation Network South London, named as one of the delivery partners on a project testing new ways to detect high blood pressure and irregular heart rhythms.

Overview

  • £22m from London’s £30m share of the Local Innovation Partnerships Fund, a UK Research and Innovation (UKRI) programme worth up to £500m across the country.
  • Three projects: £5m to a King’s College London and BioInnovation Institute venture builder for heart and metabolic disease; £5m to PHIX London, led by UCLPartners in the Harley Street Health District; £12m to the London Quantum Cluster.
  • Where: the projects are centred on the Knowledge Quarter around King’s Cross, Bloomsbury and Euston, Harley Street and West London. The boroughs listed as partners are Hammersmith & Fulham, Camden and Islington.
  • Still to come: about £8m of London’s allocation has not yet been handed out; City Hall says it will be allocated “in due course”.

The three projects

According to the Mayor’s office, the money will go to:

  • Frontier Innovation in Cardiometabolic Disease: Venture Builder, £5m. Co-led by BioInnovation Institute (BII) UK Ltd and King’s College London, it aims to turn research into new businesses developing treatments and medical technology that could detect heart disease earlier and prevent serious complications.
  • PHIX London, £5m. Led by UCLPartners, working with NHS and private healthcare providers in the Harley Street Health District, it will help firms test and scale new health technology, including better ways to detect and monitor high blood pressure and irregular heart rhythms. Its delivery partners are the Harley Street Health District, the investor AlbionVC and London’s three health innovation networks: Imperial College Health Partners, UCLPartners and the Health Innovation Network South London.
  • London Quantum Cluster, £12m. A coalition led by UCL, Imperial College London and King’s College London, based in the Knowledge Quarter and the WestTech London area in West London, including White City. It will help companies test quantum technology and raise investment, with uses the release lists in healthcare, transport, finance, energy and defence. Industry partners include IBM, Nvidia, Amazon and Canary Wharf Group.

The three projects come with more than £98m of match funding, some of it pledged rather than paid, which City Hall says brings the combined investment to more than £120m.

Why heart health is the target

The two health projects focus on cardiometabolic disease: obesity, diabetes and heart disease. City Hall calls these a leading cause of death and health inequalities, saying they fall hardest on Londoners on lower incomes and make it harder for people to work.

It says targeted improvements in treating high blood pressure alone could prevent more than 1,200 heart attacks, 1,800 strokes and almost 1,000 deaths in London, saving the NHS around £46m and social care around £12m. The figures are for London as a whole; the release gives no borough breakdown.

Professor Kevin Fenton, Regional Director of Public Health for NHS London and the Office for Health Improvement and Disparities (OHID) London, said: “Preventing cardiovascular disease (CVD) is one of London’s biggest public health priorities, and achieving our ambitions will require new ideas, stronger partnerships and faster adoption of proven innovations.

“These two complementary proposals connect research, venture development, clinical testing and NHS implementation, helping promising discoveries reach the people and communities who need them most. Together, they could strengthen London’s Million Hearts and Minds prevention programme, reduce inequalities and position London as a global leader in cardiovascular innovation.”

City Hall says the money also supports London’s bid to become a Health Innovation Zone, bringing the NHS, researchers and businesses together so new treatments reach patients faster, starting with heart health.

What the Mayor said

Speaking at the launch of the week, Sadiq Khan was expected to say: “London is one of the most exciting life sciences hubs in the world, thanks to our unique combination of world-leading research, clinical innovation and commercial expertise. But now we want to go even further and make London not just the European capital for life sciences, but the world capital.

“Through the Local Innovation Partnerships Fund, we’re providing a new shot in the arm for London’s life sciences sector, by investing £22 million into three innovative projects. Our commitment has also helped unlock nearly £100 million in match funding, sparking a chain reaction of investment that will create jobs, drive growth and fast-track innovation.”

Professor Sir Ian Chapman, chief executive of UKRI, said the fund’s investments “will add to that mix”, with life sciences and quantum technology “among the areas it concentrates upon”.

Laura Citron, chief executive of London & Partners and chair of the Frontier Innovation Board, which chose the funding priorities, said: “London is full of brilliant ideas and talented people. Helping those ideas succeed here has the potential to make life better for Londoners, but it also means creating exciting careers, especially in new industries like quantum.”

The sector in numbers

City Hall says London has more than 2,700 life sciences companies and around 40,000 jobs in the sector. London & Partners, analysing Dealroom figures, says London life sciences firms have raised $3.2bn in venture capital so far in 2026, 35% more than the $2.4bn raised in the whole of 2025, and more than three times the $933m raised in Paris.

London Life Sciences Week is run by the UK BioIndustry Association, MedCity and London & Partners, and City Hall says it brings more than 5,000 industry leaders, innovators and investors to the capital. The projects were chosen through an open call run by the Greater London Authority and assessed by an independent panel convened by UKRI; the two bodies will manage the grants.

Source: Mayor of London press office.